Weak anti –Severe Acute Respiratory Syndrome Coronavirus 2 antibody response after the first injection of an mRNA Coronavirus Disease 2019 vaccine in kidney transplant recipients
International recommendations on coronavirus disease 2019 (COVID-19) vaccine distribution have given priority to immunocompromised patients, including kidney transplant recipients (KTRs).1,2 Unfortunately, this guidance has been released without inclusion of this clinical population in vaccine clinical trials. In an effort to shed light on the efficacy and safety of an mRNA COVID-19 vaccine in KTRs, this preliminary study was undertaken to investigate the anti –severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody response after the first injection.
Source: Kidney International - Category: Urology & Nephrology Authors: Ilies Benotmane, Gabriela Gautier-Vargas, Noelle Cognard, Jerome Olagne, Francoise Heibel, Laura Braun-Parvez, Jonas Martzloff, Peggy Perrin, Bruno Moulin, Samira Fafi-Kremer, Sophie Caillard Tags: Letter to the Editor Source Type: research
More News: Clinical Trials | Coronavirus | COVID-19 | Kidney Transplant | Kidney Transplantation | Respiratory Medicine | SARS | Study | Transplant Surgery | Transplants | Urology & Nephrology | Vaccines